文献速递基础与转化研究真实世界研究与卫生经济

46基因组合检测用于实体瘤基因组分析的临床适用性与成本:英国国家医疗服务体系的回顾性验证与前瞻性审核

Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
PubMed 文献 · PLoS Med · 2017-02-14

研究验证了46基因热点癌症组合检测,可从小诊断活检样本中检测多个基因。2013年英国国家医疗服务体系连续提交的351例实体瘤前瞻性病例中,97%(342/351)测序成功,87%(296/342)检出至少一个突变,35%(122/351)检出局部可操作突变;每位患者成本339英镑(449美元),低于进行两到三项以上单基因检测。

要点

  • 46基因组合检测在97%(342/351)实体瘤样本中测序成功,与已知突变100%一致。
  • 87%(296/342)肿瘤检出至少一个突变,35%(122/351)患者检出局部可操作突变。
  • 每位患者成本339英镑(449美元),低于进行两到三项以上单基因检测。

核心结论

  • 更广泛的肿瘤测序可识别有助于改善常规癌症诊疗临床决策的突变,可能改善患者结局,且对医疗提供方而言成本可负担。

研究设计与样本

  • 研究验证了46基因热点癌症组合检测,可从小诊断活检样本中进行多基因检测。
  • 2013年1月1日至2013年12月31日,在英国国家医疗服务体系背景下,对351例连续提交的前瞻性实体瘤病例进行测序,包括非小细胞肺癌、结直肠癌和黑色素瘤。
  • 经组织学评估后,对福尔马林固定石蜡包埋切片中肿瘤富集区域进行宏切割、DNA提取、二代测序,并使用以Torrent Suite软件为中心的分析流程进行分析。
  • 中位周转时间为七个工作日,生成整合临床报告,指明检测到的变异,包括具有潜在诊断、预后、治疗或临床试验入组意义的变异。
  • 收集伴随的表型数据,并对组合检测与单基因检测进行详细成本分析,以评估常规患者护理的可负担性。

主要发现

  • 前瞻性队列中组合测序对97%(342/351)的肿瘤样本成功,与已知突变(使用cobas检测法检出)显示100%一致性。
  • 87%(296/342)的肿瘤中检出至少一个突变。
  • 122/351例患者(35%)检出局部可操作突变(即有可用靶向治疗或临床试验)。
  • 40例患者接受了靶向治疗,其中22/40例(55%)仅因使用组合检测而接受。
  • 检查已发表的靶向治疗潜在疗效数据显示,黑色素瘤和非小细胞肺癌患者中理论上可操作突变(即靶向治疗可能适用的突变)分别为66%(71/107)和39%(41/105)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究局限性包括使用福尔马林固定石蜡包埋样本,其不总能提供高质量DNA。
  • 研究局限性包括使用「真实世界」数据:提交病例进行测序并不总是遵循临床指南,意味着当检测到突变时,患者并不总是因临床原因符合靶向治疗条件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Single gene tests to predict whether cancers respond to specific targeted therapies are performed increasingly often. Advances in sequencing technology, collectively referred to as next generation sequencing (NGS), mean the entire cancer genome or parts of it can now be sequenced at speed with increased depth and sensitivity. However, translation of NGS into routine cancer care has been slow. Healthcare stakeholders are unclear about the clinical utility of NGS and are concerned it could be an expensive addition to cancer diagnostics, rather than an affordable alternative to single gene testing. METHODS AND FINDINGS: We validated a 46-gene hotspot cancer panel assay allowing multiple gene testing from small diagnostic biopsies. From 1 January 2013 to 31 December 2013, solid tumour samples (including non-small-cell lung carcinoma [NSCLC], colorectal carcinoma, and melanoma) were sequenced in the context of the UK National Health Service from 351 consecutively submitted prospective cases for which treating clinicians thought the patient had potential to benefit from more extensive genetic analysis. Following histological assessment, tumour-rich regions of formalin-fixed paraffin-embedded (FFPE) sections underwent macrodissection, DNA extraction, NGS, and analysis using a pipeline centred on Torrent Suite software. With a median turnaround time of seven working days, an integrated clinical report was produced indicating the variants detected, including those with potential diagnostic, prognostic, therapeutic, or clinical trial entry implications. Accompanying phenotypic data were collected, and a detailed cost analysis of the panel compared with single gene testing was undertaken to assess affordability for routine patient care. Panel sequencing was successful for 97% (342/351) of tumour samples in the prospective cohort and showed 100% concordance with known mutations (detected using cobas assays). At least one mutation was identified in 87% (296/342) of tumours. A locally actionable mutation (i.e., available targeted treatment or clinical trial) was identified in 122/351 patients (35%). Forty patients received targeted treatment, in 22/40 (55%) cases solely due to use of the panel. Examination of published data on the potential efficacy of targeted therapies showed theoretically actionable mutations (i.e., mutations for which targeted treatment was potentially appropriate) in 66% (71/107) and 39% (41/105) of melanoma and NSCLC patients, respectively. At a cost of £339 (US$449) per patient, the panel was less expensive locally than performing more than two or three single gene tests. Study limitations include the use of FFPE samples, which do not always provide high-quality DNA, and the use of "real world" data: submission of cases for sequencing did not always follow clinical guidelines, meaning that when mutations were detected, patients were not always eligible for targeted treatments on clinical grounds. CONCLUSIONS: This study demonstrates that more extensive tumour sequencing can identify mutations that could improve clinical decision-making in routine cancer care, potentially improving patient outcomes, at an affordable level for healthcare providers.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Hamblin A, Wordsworth S, Fermont JM, et al. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service. PLoS Med. 2017. PMID: 28196074. doi:10.1371/journal.pmed.1002230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。